This article is more than 5 years old. Information may no longer be current.

Study: NewIris safe, well tolerated 1 year after implantation

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SANTIAGO, Chile — An artificial cosmetic iris can be safely used and will not result in significant endothelial cell loss, according to a surgeon speaking here. The lens was designed for use in patients with coloboma as well as for consumer use, according to company materials.

Delary Alberto Kahn, MD, who developed the NewIris (Kahn Medical Devices), implanted it in 24 eyes of 12 patients and then compared preoperative and postoperative endothelial cell loss, corneal homeostasis, aqueous humor flow and intraocular tensions. Follow-up was 1 year after implantation.

Best preop vision was preserved, and no statistically significant difference was found in endothelial cell loss, endothelial permeability or flow of the aqueous humor.

“NewIris is well tolerated following 1 year follow-up,” Dr. Kahn said.

However, Dr. Kahn said there was a small increase in IOP, and one patient had to be explanted due to iritis and ocular hypertension.

“The NewIris implant is safe if proper attention is paid to the surgical details and patient selection,” Dr. Kahn said.